Core Insights - ONWARD Medical N.V. has appointed Lucas Buchanan as a non-executive member of its Board of Directors, enhancing its leadership team as it aims to grow its business and fulfill its mission to restore movement and function for individuals with spinal cord injuries and other movement disabilities [1][2] Company Overview - ONWARD Medical is a leading neurotechnology company focused on pioneering therapies to restore movement, function, and independence in individuals with spinal cord injuries (SCI) and other movement disabilities [4] - The company has developed ARC Therapy, which has received ten Breakthrough Device Designations from the US FDA, and its ARC-EX System is cleared for commercial sale in the US [4] - ONWARD is also working on an investigational implantable system called ARC-IM, which may include an implanted brain-computer interface (BCI) [4] Leadership and Expertise - Lucas Buchanan brings over 25 years of experience in commercialization, operations, business development, investing, and finance, having previously served as COO and CFO at Silk Road Medical, leading the company to its IPO in 2019 and subsequent acquisition by Boston Scientific in 2024 [2][6] - Buchanan is an active investor and currently serves on the boards of several medical technology companies, showcasing his extensive involvement in the healthcare sector [3][6] Strategic Vision - The appointment of Buchanan is seen as a strategic move to leverage his unique experiences as an operator and investor to help ONWARD Medical achieve its ambitions and deliver hope to millions affected by spinal cord injuries and movement disabilities [2][3]

Core Insights - ONWARD Medical N.V. announces changes to its Board of Directors, highlighting the appointment of Professor Tim Denison and the departure of Professor Gregoire Courtine [2][5][7] Company Overview - ONWARD Medical is a leading neurotechnology company focused on developing therapies to restore movement and function in individuals with spinal cord injuries (SCI) and other movement disabilities [10][11] - The company has developed ARC Therapy, which has received 10 Breakthrough Device Designations from the US FDA, and its ARC-EX System is cleared for commercial sale in the US [10] Board Changes - Professor Tim Denison has been appointed to the Board, taking over the seat previously held by Professor Gregoire Courtine, who will continue as Co-Founder and Science Advisor [3][5][8] - Denison brings extensive experience in neurotechnology, having previously served as Vice President of Research & Core Technology at Medtronic and is a co-founder of Amber Therapeutics [4][8] Research and Development Focus - The Neuro-X Institute, directed by Courtine, is a multidisciplinary research hub aimed at accelerating therapies for neurological disorders, while NeuroRestore focuses on recovery therapies for SCI, Parkinson's disease, and stroke [6][10] - ONWARD Medical's commitment to innovation is underscored by its ongoing development of investigational products, including the ARC-IM system [10][18]

Company Overview - ONWARD Medical N.V. is a leading neurotechnology company focused on developing therapies to restore movement, function, and independence for individuals with spinal cord injuries and other movement disabilities [3][4] - The company has developed ARC Therapy, which has received ten Breakthrough Device Designations from the US FDA [3] - The ARC-EX System is cleared for commercial sale in the US, while the investigational ARC-IM system is under development [3][9] Recent Developments - All proposed resolutions at the Annual General Meeting of Shareholders (AGM) held on June 11, 2025, in Amsterdam were approved [1][2] - The meeting took place at 4:00 PM CET, and details of the resolutions can be found on the company's Investor Relations website [2] Corporate Structure - ONWARD Medical is headquartered in the Netherlands, with a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts [4] - The company is listed on Euronext Paris, Brussels, and Amsterdam under the ticker ONWD, and its US ADRs are traded on OTCQX under the ticker ONWRY [4]

Core Insights - ONWARD Medical N.V. has successfully implanted its investigational ARC-BCI Therapy in two additional individuals with spinal cord injury, bringing the total to five successful implants, reinforcing its leadership in BCI-enabled movement solutions [1][2][4] Group 1: Company Achievements - The latest procedures were performed at Centre Hospitalier Universitaire Vaudois in Switzerland, showcasing the company's collaboration with leading medical professionals [2] - The fourth procedure involved a 48-year-old man with a spinal cord injury from 2024, while the fifth was on a 37-year-old woman with an injury from 2011, indicating the therapy's application across different injury timelines [3] - The CEO of ONWARD Medical emphasized the importance of these procedures in advancing understanding of the therapy and moving closer to enabling thought-driven movement for individuals with paralysis [4] Group 2: Technology and Research - The ARC-BCI System combines brain-computer interface technology with spinal cord stimulation to create a wireless connection that allows thought-driven movement after paralysis, utilizing AI to decode brain signals [4] - The therapy is part of ongoing clinical feasibility studies supported by grants from the European Innovation Council and the Christopher & Dana Reeve Foundation, indicating strong institutional backing [5] - The therapy has been recognized with Breakthrough Device Designation by the FDA, highlighting its potential impact in the medical field [4] Group 3: Media and Public Engagement - ONWARD ARC-BCI Therapy was featured on CBS 60 Minutes, enhancing public awareness and interest in the therapy and its potential benefits for individuals with spinal cord injuries [6][8]

Core Points - ONWARD Medical N.V. is a medical technology company focused on developing spinal cord stimulation therapies to restore movement and independence for individuals with spinal cord injuries and other movement disabilities [1][3] - The company will hold its 2025 Annual General Meeting of Shareholders (AGM) on June 11, 2025, in Amsterdam, with a record date for participation set for May 14, 2025 [1][2] Company Overview - ONWARD Medical has developed ARC Therapy, which has received ten Breakthrough Device Designations from the US FDA, and its ARC-EX System is cleared for commercial sale in the US [3] - The company is also working on an investigational implantable system called ARC-IM, which may include a brain-computer interface [3] - The company is headquartered in the Netherlands, with additional facilities in Switzerland and a US office in Boston, Massachusetts [4] AGM Resolutions - Key resolutions proposed for the AGM include the adoption of annual accounts for the financial year 2024, implementation of the compensation policy for 2024, and the appointment of new non-executive directors [4] - The board seeks authorization to issue ordinary shares and acquire shares in the company's capital, with specific limits on the percentage of issued share capital [4]

Core Insights - ONWARD Medical N.V. has filed its Annual Report for the fiscal year ended December 31, 2024, with the Dutch Authority for the Financial Markets (AFM) [1] - The company has also released its 2024 Sustainability Report and received a silver medal from EcoVadis for business sustainability ratings [2] - CEO Dave Marver highlighted that 2024 was transformative for ONWARD, emphasizing the company's mission to restore movement and independence for individuals with spinal cord injuries [2] Company Overview - ONWARD Medical is focused on creating therapies aimed at restoring movement, function, and independence for people with spinal cord injuries and other movement disabilities [3] - The company has developed ARC Therapy, which has received ten Breakthrough Device Designations from the US FDA, and its ARC-EX System is cleared for commercial sale in the US [3] - ONWARD is also working on an investigational implantable system called ARC-IM, which may include a brain-computer interface [3] Locations and Listings - The company is headquartered in the Netherlands, with a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts [4] - ONWARD Medical is listed on Euronext Paris, Brussels, and Amsterdam under the ticker ONWD, and its US ADRs can be traded on OTCQX under the ticker ONWRY [4]